Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q2 2022 on August 9, 2022, before U.S. markets open. The company will host a conference call at 8:30 a.m. EDT to discuss these results and the business outlook. The conference call will be available for live streaming on their Investor Relations website, with a replay to follow. SOPHiA GENETICS is focused on data-driven medicine and serves over 790 institutions globally with its SOPHiA DDM™ Platform, which analyzes multimodal data for healthcare and research purposes.

SOPHiA GENETICS held its Annual General Meeting on June 15, 2022, in St-Sulpice, Switzerland. Shareholders approved all agenda items, with detailed voting results available on the Company's website and to be filed with the SEC. Jean-Michel Cosséry was welcomed as a new board member, bringing over 25 years of industry experience. SOPHiA GENETICS aims to standardize data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 790 institutions worldwide.

SOPHiA GENETICS (Nasdaq: SOPH) has published its inaugural Environmental, Social and Governance (ESG) Impact Summary. This document outlines the Company's policies and initiatives related to innovation, patient data protection, and employee empowerment. According to Co-Founder and CEO Dr. Jurgi Camblong, the report marks the initial steps in their ESG journey, reflecting their commitment to patient care and sustainable healthcare. The ESG Impact Summary is accessible via their website and aims to enhance transparency about the Company’s practices in these vital areas.

SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with IDIBAPS and Diagnóstica Longwood to enhance Chronic Lymphocytic Leukemia (CLL) care at the European Hematology Association Congress. This partnership aims to consolidate various guideline recommendations into a single application, improving CLL characterization and research practices in Iberia. Leveraging the SOPHiA DDM™ Platform, hematopathologists can access essential guidelines and identify CLL-specific genes, potentially enhancing patient care for the 100,000+ global annual CLL cases.

SOPHiA GENETICS provided an update on its DEEP-Lung-IV clinical study during the 2022 ASCO Annual Meeting. The study focuses on predicting patient response to immunotherapy using multimodal data analysis. Currently, 19 sites across 7 countries have recruited over 500 patients. Early findings suggest promising potential for identifying predictive signatures for individual patients. Additionally, an agreement with GE Healthcare aims to enhance radiomics analysis workflows. Insights from this study could significantly impact precision medicine for stage IV non-small cell lung cancer.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q1 2022 revenue of $10.9 million, marking a year-over-year growth of 21%. Excluding COVID-19 revenues, the constant currency growth reached 35%. The company maintains its 2022 revenue growth guidance of 30% to 35%, despite a stronger U.S. dollar impacting reported figures. The total genomic profiles analyzed surpassed 1,000,000, and total recurring customers increased to 384. However, the operating loss rose to $25 million, up from $14.1 million in Q1 2021, with a net loss of $25.5 million or $0.40 per share.

SOPHiA GENETICS (Nasdaq: SOPH) announced the nomination of Jean-Michel Cosséry to its Board of Directors. His appointment will be proposed at the Annual General Meeting on June 15, 2022. Cosséry brings over 25 years of experience in the med-tech and pharmaceutical sectors, having held key positions at Novartis, GE Healthcare, and Eli Lilly. CEO Jurgi Camblong highlighted Cosséry's diverse expertise as an asset for accelerating growth in oncology and biopharma. SOPHiA GENETICS aims to establish data-driven medicine as a standard of care globally, serving over 790 institutions.

SOPHiA GENETICS (Nasdaq: SOPH) announced that CFO Ross Muken will participate in the J.P. Morgan 50th Annual Global Technology, Media, and Communications Conference in Boston on May 24, 2022. The company's management will also engage in multiple investor meetings during the event. SOPHiA GENETICS is committed to advancing data-driven medicine through its innovative SOPHiA DDM™ Platform, which is utilized by over 790 healthcare institutions globally. For investor inquiries, contact Jennifer Pottage, Head of Investor Relations.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that its SOPHiA DDM™ Platform has successfully analyzed one million genomic profiles, marking a significant achievement in data-driven medicine. This milestone illustrates the platform's rapid growth, having doubled its analyzed profiles in just under two years. The technology is utilized across over 790 healthcare institutions worldwide, enhancing the accuracy of genomic variant detection and facilitating improved patient care. Collaborations, such as with GE Healthcare, further support advancements in cancer treatment by optimizing therapeutic targeting.